Wide Ranks

INKT

MiNK Therapeutics, Inc.

0.7201

Top Statistics
Market Cap 28 M Forward PE -1.87 Revenue Growth 0.00 %
Current Ratio 0.93 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.33 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 9 M Total Cash Per Share 0.2360 Total Debt 4 M
Total Debt To Equity Current Ratio 0.93 Book Value Per Share -0.5220
All Measures
Short Ratio 110.00 % Message Board Id finmb_1679217092 Shares Short Prior Month 48631
City New York Uuid 8e937e64-1037-36f6-8809-414881fb7391 Previous Close 0.7240
First Trade Date Epoch Utc 1 B Book Value -0.5220 Beta 0.0480
Total Debt 4 M Volume 13241 Fifty Two Week Low 0.5700
Total Cash Per Share 0.2360 Shares Short Previous Month Date 1 B Target Median Price 7.00
Max Age 86400 Recommendation Mean 1.25 Sand P52 Week Change 0.3133
Target Mean Price 6.67 Net Income To Common -17089964 Short Percent Of Float 0.0035
Implied Shares Outstanding 39 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 34130 Average Volume10days 34130 Total Cash 9 M
Next Fiscal Year End 1 B Held Percent Insiders 0.7465 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 0.7240
Target Low Price 4.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.7206
Open 0.7160 Free Cashflow -8162204 State NY
Dividend Yield 0.00 % Return On Assets -0.9725 Time Zone Short Name EST
Trailing Eps -0.3700 Day Low 0.7160 Address1 149 Fifth Avenue
Shares Outstanding 39 M Price Hint 4 Target High Price 9.00
Website https://minktherapeutics.com 52 Week Change -0.3143 Average Volume 36235
Forward Eps -0.4200 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 91.80 % Is_sp_500 False Regular Market Day High 0.7285
Profit Margins 0.00 % Fifty Two Week High 1.90 Day High 0.7285
Shares Short 51735 Regular Market Open 0.7160 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0013
Operating Cashflow -12077965 Currency USD Time Zone Full Name America/New_York
Market Cap 28 M Is_nasdaq_100 False Zip 10010
Quote Type EQUITY Industry Biotechnology Long Name MiNK Therapeutics, Inc.
Regular Market Day Low 0.7160 Held Percent Institutions 0.0225 Current Price 0.7201
Address2 Suite 500 Enterprise To Ebitda -1.33 Financial Currency USD
Current Ratio 0.93 Industry Disp Biotechnology Number Of Analyst Opinions 3
Country United States Float Shares 10 M Two Hundred Day Average 0.8712
Enterprise Value 22 M Forward PE -1.87 Regular Market Volume 13241
Ebitda -17249290 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.

Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.

The company has a collaboration with autonomous therapeutics, inc.

to develop novel therapies targeting metastatic tumors.

The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York.

MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.